Montana is currently home to 259 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Billings, Missoula, Great Falls and Kalispell. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368
Recruiting
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).
Gender:
ALL
Ages:
Between 18 years and 105 years
Trial Updated:
07/24/2025
Locations: Providence Saint Patrick Hospital, Missoula, Montana
Conditions: Aortic Stenosis
Register for Updates
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401
Recruiting
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
07/24/2025
Locations: Saint Vincent Frontier Cancer Center, Billings, Montana
Conditions: Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Acute Myeloid Leukemia, Metastatic Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Multiple Myeloma, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Fallopian Tube Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Melanoma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Triple-Negative Breast Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
Register for Updates
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760
Recruiting
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: St. Vincent Frontier Cancer Center ( Site 0043), Billings, Montana
Conditions: Non-small Cell Lung Cancer
Register for Updates
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225
Recruiting
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana
Conditions: Endometrial Serous Adenocarcinoma, Uterine Corpus Carcinosarcoma, Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Undifferentiated Carcinoma
Register for Updates
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
NCT06029270
Recruiting
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana
Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Register for Updates
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
NCT04840602
Recruiting
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Saint Vincent Frontier Cancer Center, Billings, Montana
Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Register for Updates
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673
Recruiting
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Gender:
ALL
Ages:
Between 45 years and 70 years
Trial Updated:
07/23/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana
Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Register for Updates
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204
Recruiting
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana
Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
Register for Updates
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Arthrosi Investigative Site (664), Missoula, Montana
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Register for Updates
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT06498635
Recruiting
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana
Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Register for Updates
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Billings Clinic, Billings, Montana
Conditions: Type 2 Diabetes
Register for Updates
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 253147, Billings, Montana
Conditions: Non Small Cell Lung Cancer
Register for Updates